Diabetes researchers from The Kids Research Institute Australia and Perth Children’s Hospital are excited to be taking part in the national Insulin and Abatacept (IAA) trial in type 1 diabetes.
IAA is a randomised controlled trial testing whether the combination of two safe disease-modifying therapies called abatacept and nasal insulin slows down the immune attack on the insulin-producing (beta) cells of people with newly-diagnosed type 1 diabetes. Abatacept is a disease-modifying medication approved for treatment of rheumatoid arthritis in both adults and children.
They are looking for participants aged 6 – 21years old to be involved in the study and must;
- Have been diagnosed with type 1 diabetes within 100 days
- Have at least 1 diabetes antibody
- Have random C-peptide >0.3 nmol/L
- Willing to use CGM for duration of trial
- Fully vaccinated (including Covid-19)
To find out more information, visit https://atic.svi.edu.au/clinical-trials/
If you are interested in taking part in this study and would like more information, please contact Alison Roberts at Alison.Roberts@health.wa.gov.au.
